AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14565653 — intervention group
Group type: COMPARATOR
Intervention: DATVP (daunorubicin 60 mg/m2 daily, days 1, 2 and 3; cytarabine 25 mg/m2 intravenous bolus followed by 200 mg/m2 daily as a continuous infusion on days 1‐5; 6-thioguanine 100 mg/m2 orally every 12 h on days 1‐5; vincristine 2 mg intravenously on days 1 and 8; prednisone 60 mg/m2/day orally, days 1‐7)
Number of subjects: 276
Study 11083681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 12
Study 11083681 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 12
Study 11083681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11083681 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (800 microg)
Number of subjects: 12
Study 22302887 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (500 mg test dose)
Number of subjects: 40
Study 22302887 — intervention group
Group type: COMPARATOR
Intervention: Placebo (48 h substitution)
Number of subjects: 40
Study 22302887 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine metabolism rate
Number of subjects: 40
Study 2070285 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation session (20 mins lying down listening to a tape)
Number of subjects: 0
Study 2070285 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured interview (the structured interview of Rosenman)
Number of subjects: 0
Study 6215496 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback training
Number of subjects: 15
Study 6215496 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training with no feedback
Number of subjects: 15
Study 6215496 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 15
Study 30529737 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates group (PEP)
Number of subjects: 60
Study 30529737 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular group (MEP)
Number of subjects: 60
Study 30529737 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study 26830893 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Program (CBP)
Number of subjects: 316
Study 26830893 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 316
Study 27761556 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/alfentanil (10 µg/kg IV alfentanil)
Number of subjects: 52
Study 27761556 — intervention group
Group type: COMPARATOR
Intervention: Propofol/ketamine (0.5 mg/kg IV ketamine)
Number of subjects: 52
Study 24976448 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of rosuvastatin 10 mg with metformin 750 mg
Number of subjects: 36
Study 24976448 — intervention group
Group type: COMPARATOR
Intervention: Monoadministration of rosuvastatin 10 mg
Number of subjects: 36
Study 24976448 — intervention group
Group type: COMPARATOR
Intervention: Monoadministration of metformin 750 mg
Number of subjects: 36
Study 24976448 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (rosuvastatin, metformin, and coadministration)
Number of subjects: 36
Study 22212240 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg administered 30 min prior to exercise)
Number of subjects: 16
Study 22212240 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 16
Study 20707767 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin (5 or 10 mg/day, flexibly dosed)
Number of subjects: 158
Study 20707767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 17627692 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG‐IUS)
Number of subjects: 66
Study 17627692 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal balloon ablation (TBA)
Number of subjects: 66
Study 17627692 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 66
Study 15899022 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-coloured post-and-core with composite core (Tetric Ceram)
Number of subjects: 50
Study 15899022 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia post (Cosmopost) with composite core (Tetric Ceram)
Number of subjects: 50
Study 15899022 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia post (Cosmopost) with custom made ceramic core (Cosmo Ingot)
Number of subjects: 50
Study 15899022 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fibre-reinforced post (FRC Postec) with composite core (Tetric Ceram)
Number of subjects: 50
Study 15899022 — intervention group
Group type: COMPARATOR
Intervention: Control group: root-filled incisors without posts
Number of subjects: 50
Study 12073726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortify (surface sealant)
Number of subjects: 50
Study 12073726 — intervention group
Group type: EXPERIMENTAL
Intervention: Unibond (low-viscosity resin system)
Number of subjects: 50
Study 12073726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorseal (low-viscosity resin system)
Number of subjects: 50
Study 12073726 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surface sealing)
Number of subjects: 50
Study 10384580 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled clinical trial evidence
Number of subjects: 76
Study 10384580 — intervention group
Group type: COMPARATOR
Intervention: Locally developed recommendations
Number of subjects: 76
Study 10384580 — intervention group
Group type: COMPARATOR
Intervention: No evidence
Number of subjects: 76
Study 7644734 — intervention group
Group type: EXPERIMENTAL
Intervention: APCT
Number of subjects: 18
Study 7644734 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipiodol‐CT
Number of subjects: 18
Study 2663957 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary sheath system 1
Number of subjects: 6
Study 2663957 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary sheath system 2
Number of subjects: 6
Study 2663957 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary sheath system 3
Number of subjects: 6
Study 2663957 — intervention group
Group type: COMPARATOR
Intervention: Control (no sheath system)
Number of subjects: 6
Study 2663957 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance of urinary sheath systems
Number of subjects: 6
Study 402275 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine infusion during surgery with glucose load (20 g)
Number of subjects: 0
Study 402275 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate solution infusion during surgery with glucose load (20 g)
Number of subjects: 0
Study 402275 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate solution and phentolamine infusion during surgery (control group)
Number of subjects: 0
Study 31335204 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglyca mobile application
Number of subjects: 80
Study 31335204 — intervention group
Group type: COMPARATOR
Intervention: Routine calculations (Control group)
Number of subjects: 80
Study 26833853 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking training (NW)
Number of subjects: 33
Study 26833853 — intervention group
Group type: COMPARATOR
Intervention: Free walk (FW)
Number of subjects: 33
Study 25590308 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline spray
Number of subjects: 86
Study 25590308 — intervention group
Group type: EXPERIMENTAL
Intervention: Squeeze bottle
Number of subjects: 86
Study 24015773 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed antismoking PSA
Number of subjects: 183
Study 24015773 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed antismoking PSA
Number of subjects: 183
Study 24015773 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondhand smoke PSA
Number of subjects: 183
Study 24015773 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking addiction PSA
Number of subjects: 183
Study 21792057 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A (0.05%) twice a day plus preservative-free artificial tears four times a day for 4 months
Number of subjects: 42
Study 21792057 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free artificial tears four times a day for 4 months
Number of subjects: 42
Study 19327530 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (100 micromol/L)
Number of subjects: 40
Study 19327530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16637752 — intervention group
Group type: EXPERIMENTAL
Intervention: Symhedonia for high-attachment targets
Number of subjects: 7
Study 16637752 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathy
Number of subjects: 7
Study 16637752 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathy and symhedonia
Number of subjects: 7
Study 16637752 — intervention group
Group type: EXPERIMENTAL
Intervention: Symhedonia
Number of subjects: 7
Study 12910806 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal bath plus muds (Group A)
Number of subjects: 18
Study 12910806 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal bath plus muds (Group C)
Number of subjects: 18
Study 12910806 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 18
Study 11198133 — intervention group
Group type: EXPERIMENTAL
Intervention: Single own brand cigarette
Number of subjects: 0
Study 11198133 — intervention group
Group type: COMPARATOR
Intervention: Control (abstained smokers)
Number of subjects: 0
Study 8813910 — intervention group
Group type: EXPERIMENTAL
Intervention: Unoplast Unometer 500
Number of subjects: 45
Study 8813910 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Ureofix 511
Number of subjects: 45
Study 8813910 — intervention group
Group type: COMPARATOR
Intervention: Kendall Curity 4000
Number of subjects: 45
Study 1563054 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal prongs (Group NP, 4 L.min‐1)
Number of subjects: 40
Study 1563054 — intervention group
Group type: COMPARATOR
Intervention: Simple facemask (Group FM, 8 L.min‐1)
Number of subjects: 40
Study 4054191 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 18
Study 4054191 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 18
Study 30135030 — intervention group
Group type: EXPERIMENTAL
Intervention: Etifoxine (100 mg)
Number of subjects: 30
Study 30135030 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 30
Study 27902584 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone+fentanyl
Number of subjects: 90
Study 27902584 — intervention group
Group type: EXPERIMENTAL
Intervention: tropisetron+fentanyl
Number of subjects: 90
Study 27902584 — intervention group
Group type: COMPARATOR
Intervention: fentanyl
Number of subjects: 90
Study 24773915 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cream delivering narrow-band ultraviolet B, average of 38 sessions
Number of subjects: 0
Study 24773915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22549370 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal cholecystectomy (TVC)
Number of subjects: 47
Study 22549370 — intervention group
Group type: COMPARATOR
Intervention: Single incision laparoscopic cholecystectomy (SILC)
Number of subjects: 47
Study 20353858 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase injection for MCP joint contracture
Number of subjects: 8
Study 20353858 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase injection for PIP joint contracture
Number of subjects: 8
Study 20353858 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall clinical success rating
Number of subjects: 8
Study 20353858 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial response to collagenase injection
Number of subjects: 8
Study 20353858 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term recurrence rates
Number of subjects: 8
Study 18561583 — intervention group
Group type: EXPERIMENTAL
Intervention: Solubilized BPO 5% gel
Number of subjects: 23
Study 18561583 — intervention group
Group type: COMPARATOR
Intervention: BPO 5%/clindamycin 1% combination product
Number of subjects: 23
Study 14759375 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alteplase (50 mg) and tirofiban (0.4 microg/kg/min/30 minute bolus; infusion of 0.1 microg/kg/minute)
Number of subjects: 144
Study 14759375 — intervention group
Group type: COMPARATOR
Intervention: Standard strategy with either full-dose alteplase (100 mg) or stenting PCI
Number of subjects: 144
Study 14759375 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting PCI with tirofiban
Number of subjects: 144
Study 14759375 — intervention group
Group type: COMPARATOR
Intervention: Standard stenting PCI
Number of subjects: 144
Study 14759375 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctive regimens with tirofiban
Number of subjects: 144
Study 14759375 — intervention group
Group type: COMPARATOR
Intervention: Standard regimens
Number of subjects: 144
Study 10918826 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 10918826 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTCA)
Number of subjects: 0
Study 10918826 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study 10918826 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 0
Study 10918826 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 0
Study 9293416 — intervention group
Group type: EXPERIMENTAL
Intervention: Seat tube angle of 80 degrees
Number of subjects: 14
Study 9293416 — intervention group
Group type: EXPERIMENTAL
Intervention: Seat tube angle of 74 degrees
Number of subjects: 14
Study 7688432 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg pentosanpolysulfate 3 times per day
Number of subjects: 148
Study 7688432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 3523457 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (CZ) at a dose of 150 mg/kg/day divided every 8 hours
Number of subjects: 100
Study 3523457 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (CZ)
Number of subjects: 100
Study 3523457 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with chloramphenicol and ampicillin (CA)
Number of subjects: 100
Study 29316962 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (Marx protocol)
Number of subjects: 0
Study 29316962 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care with antibiotics and chlorhexidine mouthwash)
Number of subjects: 0
Study 26385164 — intervention group
Group type: EXPERIMENTAL
Intervention: In SHAPE lifestyle intervention
Number of subjects: 192
Study 24978428 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 10
Study 24978428 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 10
Study 24978428 — intervention group
Group type: COMPARATOR
Intervention: Untreated fellow eye
Number of subjects: 10
Study 22934592 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based interactive curriculum emphasizing conciseness and clinical reasoning
Number of subjects: 132
Study 22934592 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 132
Study 22934592 — intervention group
Group type: EXPERIMENTAL
Intervention: All students after receiving the curriculum
Number of subjects: 132
Study 22934592 — intervention group
Group type: COMPARATOR
Intervention: Untrained comparison students
Number of subjects: 132
Study 19408097 — intervention group
Group type: EXPERIMENTAL
Intervention: New-Alfare
Number of subjects: 47
Study 18417739 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib administered concurrently with radiation therapy at dose levels ranging from 100 to 150 mg/m(2)/dose, followed by adjuvant tipifarnib at 200 mg/m(2)/dose for 21 consecutive days in 28-day cycles.
Number of subjects: 17
Study 15923005 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding (8 h)
Number of subjects: 151
Study 15923005 — intervention group
Group type: COMPARATOR
Intervention: Delayed oral feeding (24 h)
Number of subjects: 151
Study 12534646 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir 600 mg twice a day for 10 days
Number of subjects: 18
Study 12534646 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine 600 mg twice a day for 10 days
Number of subjects: 18
Study 12534646 — intervention group
Group type: EXPERIMENTAL
Intervention: Both amprenavir and delavirdine for 10 days
Number of subjects: 18
Study 11244724 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride 100 mg/d
Number of subjects: 49
Study 11244724 — intervention group
Group type: COMPARATOR
Intervention: Control (ordinary medication only)
Number of subjects: 49
Study 9253881 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg single dose)
Number of subjects: 0
Study 9253881 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (400 mg single dose)
Number of subjects: 0
Study 1514652 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromides (BR)
Number of subjects: 120
Study 1514652 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbitone (PB) and/or Phenytoin (PHT)
Number of subjects: 120
Study 6424697 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored elimination diets
Number of subjects: 29
Study 6424697 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium cromoglycate (SCG)
Number of subjects: 29
Study 6424697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 31018921 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (203 minutes/week)
Number of subjects: 49
Study 31018921 — intervention group
Group type: COMPARATOR
Intervention: Mind-body control group (23 minutes/week)
Number of subjects: 49
Study 31018921 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 49
Study 28815717 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic partial inferior turbinectomy (EPIT) with rhinoseptoplasty
Number of subjects: 50
Study 28815717 — intervention group
Group type: COMPARATOR
Intervention: Rhinoseptoplasty without EPIT
Number of subjects: 50
Study 26766564 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (AZL‐M) 80mg
Number of subjects: 3821
Study 26766564 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan (OLM) 40mg
Number of subjects: 3821
Study 26766564 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (VAL) 320mg
Number of subjects: 3821
Study 26766564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3821
Study 24261926 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercises (LSE)
Number of subjects: 105
Study 24261926 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy (MT)
Number of subjects: 105
Study 24261926 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercises (LSE) with modified CPR (mCPR)
Number of subjects: 105
Study 21666432 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/d) for 6 months
Number of subjects: 80
Study 21666432 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil PET examinations
Number of subjects: 80
Study 19725485 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection with lidocaine
Number of subjects: 63
Study 19725485 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 63
Study 17261398 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal protection during PCI
Number of subjects: 194
Study 17261398 — intervention group
Group type: COMPARATOR
Intervention: No distal protection during PCI
Number of subjects: 194
Study 15056486 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic treatment over 14 weeks
Number of subjects: 66
Study 15056486 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic treatment
Number of subjects: 66
Study 15056486 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls, N=73)
Number of subjects: 66
Study 11317071 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 205
Study 11317071 — intervention group
Group type: COMPARATOR
Intervention: Control (no HAART)
Number of subjects: 205
Study 9338672 — intervention group
Group type: EXPERIMENTAL
Intervention: Transscleral diode laser photocoagulation (wavelength 810 nm)
Number of subjects: 25
Study 9338672 — intervention group
Group type: COMPARATOR
Intervention: Transpupillary diode laser photocoagulation
Number of subjects: 25
Study 9338672 — intervention group
Group type: EXPERIMENTAL
Intervention: Transscleral diode laser photocoagulation
Number of subjects: 25
Study 7960384 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing frequency categories
Number of subjects: 6783
Study 7960384 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of portion sizes
Number of subjects: 6783
Study 7960384 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of additional non-dietary questions
Number of subjects: 6783
Study 2820626 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 14824A (2 mg p.o. q.d.)
Number of subjects: 6
Study 2820626 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 14824A (10 mg p.o. q.d.)
Number of subjects: 6
Study 2820626 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 6
Study 29860453 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention
Number of subjects: 13392
Study 29860453 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 13392
Study 29860453 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age at birth
Number of subjects: 13392
Study 29860453 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban versus rural residence
Number of subjects: 13392
Study 29860453 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower parental education and number of older siblings
Number of subjects: 13392
Study 29860453 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (boys vs girls)
Number of subjects: 13392
Study 27435610 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (transcutaneous electrical stimulation)
Number of subjects: 36
Study 27435610 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 36